13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001502287
Total reported value
$2.2B
$2.2B
14 檔
1.9%
During the Q2 2025 filing period, StepStone Group LP (CIK: 0001502287) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $2.2B across 14 reported positions.
StepStone Group LP executed strategic sector rebalancing during Q2 2025, establishing 4 new positions while fully exiting 6 holdings and trimming 0 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PATH | Uipath Inc - Class A | Stock-Tech | 32.65% | -4.83% | EXIT | |
| 2 | DKNG | Draftkings Inc-cl A | Stock-Consumer Disc | 18.25% | -1.68% | EXIT | |
| 3 | RBRK | Rubrik Inc-a | Stock-Tech | 10.69% | — | NEW | |
| 4 | TRDA | Entrada Therapeutics Inc | Stock-Other | 10.14% | -4.37% | — | |
| 5 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 8.03% | -2.05% | — | |
| 6 | ✓ | Neuehealth Inc | Stock-Other | 7.19% | — | — | |
| 7 | ✓ | Hillevax Inc | Stock-Other | 3.26% | — | — | |
| 8 | PAY | Paymentus Holdings Inc-a | Stock-Other | 2.57% | — | — | |
| 9 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 2.33% | -4.75% | — | |
| 10 | CXM | Sprinklr Inc-a | Stock-Other | 1.26% | — | — | |
| 11 | PDD | Pdd Holdings Inc | Stock-Consumer Disc | 1.24% | — | — | |
| 12 | IOT | Samsara Inc-cl A | Stock-Tech | 0.96% | — | — | |
| 13 | GROV | Grove Collaborative Holdings | Stock-Other | 0.87% | -0.21% | +0.08% | |
| 14 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.56% | -0.13% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PATH | Uipath Inc - Class A | +19% | — | Unchanged |
| 2 | DKNG | Draftkings Inc-cl A | +10.9% | — | Unchanged |
| 3 | RBRK | Rubrik Inc-a | +7.3% | +11.78% | Add |
| 4 | PHAT | Phathom Pharmaceuticals Inc | +5.3% | — | Unchanged |
| 5 | ✓ | Neuehealth Inc | +3.5% | — | Unchanged |
| 6 | TRDA | Entrada Therapeutics Inc | +3.1% | — | Unchanged |
| 7 | PAY | Paymentus Holdings Inc-a | +2.6% | NEW | New buy |
| 8 | ✓ | Hillevax Inc | +2% | — | Unchanged |
| 9 | CXM | Sprinklr Inc-a | +1.3% | NEW | New buy |
| 10 | PDD | Pdd Holdings Inc | +1.2% | NEW | New buy |
| 11 | IOT | Samsara Inc-cl A | +1% | NEW | New buy |
| 12 | GROV | Grove Collaborative Holdings | +0.3% | +0.08% | Add |
| 13 | TNYA | Tenaya Therapeutics Inc | +0.3% | — | Unchanged |
| 14 | OKUR | Onkure Therapeutics Inc-a | +0.2% | — | Unchanged |
| 15 | AMPL | Amplitude Inc-class A | 0% | EXIT | Sold out |
| 16 | DOCS | Doximity Inc-class A | -0.5% | EXIT | Sold out |
| 17 | FRSH | Freshworks Inc-cl A | -0.6% | EXIT | Sold out |
| 18 | ✓ | Vacasa Inc | -0.8% | EXIT | Sold out |
| 19 | BZ | Kanzhun LTD - Adr | -2.1% | EXIT | Sold out |
| 20 | ✓ | Moneylion Inc | -54.1% | EXIT | Sold out |
According to official SEC Form 13F filings, StepStone Group LP reported a total U.S. public equity portfolio value of $2.2B across 14 disclosed positions in Q2 2025.
During Q2 2025, StepStone Group LP's top holdings by market value included PATH (32.6%)、DKNG (18.3%)、RBRK (10.7%). The largest single position, PATH, represented 32.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PATH, DKNG, RBRK) accounted for 1.9% of total reported equity market value during Q2 2025.
Top New Position Initiated
PAY
市值: $1.3M
Top Position Liquidated / Trimmed
MONEYLION INC
前期市值: $52.7M
In Q2 2025, StepStone Group LP made 12 total portfolio adjustments, initiating 4 new buys, adding to 2 positions, trimming 0 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.